Reagents required for provider/patient management of outpatient care and referral site. Failure to acquire these reagents would results in a total work stoppage.
Ended Awarded
- Contract number
- HT009025FG0730036
- Awardee
-
Roche Diagnostics Corporation UEI JDMDFEZBYH36
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $15,966
Award facts
- Contract value 100% obligated
- $15,965.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Castleton, IN 46256, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $15,965.52 firm fixed-price Blanket Purchase Agreement (BPA) call to Roche Diagnostics Corporation on July 28, 2025, with completion scheduled for September 30, 2025. This contract, which carries no set-aside designation, procures diagnostic reagents essential for provider and patient management in outpatient care and referral site operations. The government description emphasizes the critical nature of these reagents, noting that failure to acquire them would result in total work stoppage. The work will be performed in Castleton, Indiana.
Roche Diagnostics Corporation, a global leader in in vitro diagnostic solutions and laboratory instrumentation, is well-positioned to fulfill this requirement through its extensive portfolio of diagnostic reagents and testing systems. As a child contract under a larger vehicle, this award represents a call against pre-negotiated terms established through GSA Schedule contracts, including the In Vitro Diagnostics, Reagents, Test (FSS-65-VII) schedule. Roche's federal contract history demonstrates significant experience supplying diagnostic technologies to the Department of Defense and other federal healthcare agencies, with prior contracts covering molecular testing, clinical chemistry, immunochemistry, and point-of-care testing capabilities. The relatively modest contract ceiling reflects the specific reagent requirements for this particular outpatient care facility.
Quick answers
Who was awarded contract HT009025FG0730036?
HT009025FG0730036 was awarded to Roche Diagnostics Corporation by Defense Health Agency (Department of Defense) on July 28, 2025.
How much is contract HT009025FG0730036 worth?
The government has obligated $15,966 on HT009025FG0730036.
Is contract HT009025FG0730036 an order under another contract?
Yes. HT009025FG0730036 is a BPA call under FA301625A0005, a blanket purchase agreement.
Was contract HT009025FG0730036 competed?
The extent of competition for HT009025FG0730036 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award